| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peritoneal Neoplasms | 12 | 2026 | 58 | 6.730 |
Why?
|
| Malaria, Vivax | 19 | 2024 | 27 | 5.110 |
Why?
|
| Colorectal Neoplasms | 14 | 2025 | 623 | 5.080 |
Why?
|
| Cytoreduction Surgical Procedures | 11 | 2026 | 51 | 4.340 |
Why?
|
| Plasmodium vivax | 19 | 2024 | 27 | 4.100 |
Why?
|
| Appendiceal Neoplasms | 8 | 2026 | 22 | 4.090 |
Why?
|
| Malaria, Falciparum | 18 | 2024 | 67 | 4.080 |
Why?
|
| Plasmodium falciparum | 19 | 2024 | 93 | 2.810 |
Why?
|
| Hyperthermia, Induced | 5 | 2023 | 56 | 2.650 |
Why?
|
| Adenocarcinoma | 10 | 2026 | 986 | 2.570 |
Why?
|
| Malaria | 12 | 2024 | 98 | 2.420 |
Why?
|
| Trans-Activators | 7 | 2025 | 705 | 2.300 |
Why?
|
| Antibodies, Protozoan | 15 | 2023 | 101 | 2.220 |
Why?
|
| Gastrointestinal Microbiome | 6 | 2025 | 837 | 1.980 |
Why?
|
| Serologic Tests | 5 | 2026 | 125 | 1.650 |
Why?
|
| Circulating Tumor DNA | 2 | 2025 | 42 | 1.620 |
Why?
|
| Homeodomain Proteins | 6 | 2025 | 568 | 1.560 |
Why?
|
| Microbiota | 3 | 2023 | 443 | 1.540 |
Why?
|
| Enhancer Elements, Genetic | 6 | 2025 | 274 | 1.540 |
Why?
|
| Retina | 6 | 2025 | 452 | 1.500 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2021 | 188 | 1.310 |
Why?
|
| Biomarkers, Tumor | 10 | 2026 | 1606 | 1.300 |
Why?
|
| Protozoan Proteins | 10 | 2023 | 130 | 1.300 |
Why?
|
| Humans | 139 | 2026 | 130422 | 1.290 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 10 | 2020 | 341 | 1.250 |
Why?
|
| Transcription Factors | 10 | 2025 | 2452 | 1.220 |
Why?
|
| Pancreatic Neoplasms | 5 | 2021 | 743 | 1.220 |
Why?
|
| Rectal Neoplasms | 4 | 2025 | 78 | 1.190 |
Why?
|
| Malaria Vaccines | 7 | 2021 | 25 | 1.170 |
Why?
|
| Photoreceptor Cells | 2 | 2021 | 90 | 1.170 |
Why?
|
| Biological Products | 4 | 2022 | 141 | 1.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 479 | 1.130 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 3 | 2024 | 152 | 1.110 |
Why?
|
| Plasmodium | 3 | 2022 | 10 | 1.040 |
Why?
|
| Survival Rate | 13 | 2025 | 2131 | 1.040 |
Why?
|
| Lung Neoplasms | 11 | 2022 | 1543 | 1.040 |
Why?
|
| Melanoma | 5 | 2022 | 918 | 0.990 |
Why?
|
| Combined Modality Therapy | 8 | 2025 | 1233 | 0.990 |
Why?
|
| Antigens, Protozoan | 10 | 2020 | 79 | 0.980 |
Why?
|
| Laparoscopy | 5 | 2025 | 541 | 0.980 |
Why?
|
| Flavivirus Infections | 1 | 2026 | 7 | 0.970 |
Why?
|
| Flavivirus | 1 | 2026 | 25 | 0.960 |
Why?
|
| Alphavirus Infections | 1 | 2026 | 12 | 0.960 |
Why?
|
| Alphavirus | 1 | 2026 | 17 | 0.960 |
Why?
|
| Epidemiological Monitoring | 1 | 2026 | 71 | 0.940 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2025 | 1276 | 0.930 |
Why?
|
| Antibodies, Viral | 3 | 2026 | 1167 | 0.840 |
Why?
|
| Proto-Oncogene Proteins B-raf | 5 | 2025 | 219 | 0.840 |
Why?
|
| Communicable Diseases | 1 | 2026 | 159 | 0.820 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2025 | 174 | 0.810 |
Why?
|
| Binding Sites | 7 | 2025 | 1149 | 0.810 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2023 | 2 | 0.800 |
Why?
|
| Hepatectomy | 1 | 2024 | 126 | 0.790 |
Why?
|
| Animals | 43 | 2026 | 33892 | 0.770 |
Why?
|
| B7-H1 Antigen | 2 | 2020 | 129 | 0.760 |
Why?
|
| Prognosis | 13 | 2025 | 4894 | 0.740 |
Why?
|
| Antineoplastic Agents | 6 | 2023 | 1796 | 0.730 |
Why?
|
| Immunoglobulin G | 13 | 2026 | 790 | 0.720 |
Why?
|
| Neoplasm Metastasis | 2 | 2024 | 706 | 0.720 |
Why?
|
| Models, Biological | 5 | 2022 | 1390 | 0.700 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2022 | 81 | 0.700 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2021 | 427 | 0.680 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2022 | 130 | 0.670 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 78 | 0.670 |
Why?
|
| Neoplasm Proteins | 4 | 2020 | 683 | 0.660 |
Why?
|
| Smegmamorpha | 1 | 2020 | 2 | 0.660 |
Why?
|
| Stomach Neoplasms | 3 | 2024 | 576 | 0.650 |
Why?
|
| Y Chromosome | 1 | 2020 | 47 | 0.650 |
Why?
|
| Coinfection | 1 | 2022 | 188 | 0.650 |
Why?
|
| Genome-Wide Association Study | 7 | 2025 | 1838 | 0.650 |
Why?
|
| Seroepidemiologic Studies | 6 | 2026 | 165 | 0.650 |
Why?
|
| RNA Interference | 8 | 2017 | 494 | 0.650 |
Why?
|
| Middle Aged | 33 | 2026 | 28383 | 0.640 |
Why?
|
| Signal Transduction | 12 | 2023 | 4674 | 0.640 |
Why?
|
| Mice | 26 | 2025 | 18188 | 0.640 |
Why?
|
| Gene Regulatory Networks | 3 | 2024 | 384 | 0.630 |
Why?
|
| Models, Statistical | 4 | 2020 | 482 | 0.630 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 74 | 0.630 |
Why?
|
| Gene Expression Regulation, Fungal | 3 | 2026 | 56 | 0.630 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2025 | 39 | 0.630 |
Why?
|
| Appendicitis | 1 | 2021 | 132 | 0.630 |
Why?
|
| Ribosomal Proteins | 3 | 2026 | 71 | 0.630 |
Why?
|
| Neutropenia | 1 | 2021 | 203 | 0.620 |
Why?
|
| Repressor Proteins | 2 | 2016 | 774 | 0.620 |
Why?
|
| Karyopherins | 2 | 2017 | 35 | 0.620 |
Why?
|
| Aged | 30 | 2026 | 20894 | 0.620 |
Why?
|
| Cell Line, Tumor | 17 | 2021 | 3715 | 0.610 |
Why?
|
| Retrospective Studies | 21 | 2026 | 17614 | 0.600 |
Why?
|
| Mesothelioma | 1 | 2020 | 93 | 0.600 |
Why?
|
| Genetics | 1 | 2019 | 24 | 0.590 |
Why?
|
| Biological Evolution | 1 | 2020 | 227 | 0.590 |
Why?
|
| Neoplasms | 7 | 2024 | 2944 | 0.590 |
Why?
|
| Female | 53 | 2026 | 70285 | 0.590 |
Why?
|
| Psychology | 1 | 2019 | 56 | 0.590 |
Why?
|
| Trachoma | 1 | 2018 | 13 | 0.580 |
Why?
|
| Genomics | 6 | 2020 | 1619 | 0.580 |
Why?
|
| Chlamydia trachomatis | 1 | 2018 | 28 | 0.580 |
Why?
|
| Drug Discovery | 2 | 2019 | 178 | 0.570 |
Why?
|
| Adult | 32 | 2026 | 31127 | 0.560 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 3 | 2020 | 325 | 0.560 |
Why?
|
| Models, Theoretical | 7 | 2017 | 363 | 0.550 |
Why?
|
| Male | 47 | 2026 | 64527 | 0.550 |
Why?
|
| MicroRNAs | 6 | 2025 | 896 | 0.550 |
Why?
|
| Biguanides | 1 | 2017 | 12 | 0.540 |
Why?
|
| Lactams | 1 | 2017 | 22 | 0.540 |
Why?
|
| Digoxin | 1 | 2017 | 37 | 0.540 |
Why?
|
| Bacteria | 2 | 2024 | 536 | 0.540 |
Why?
|
| Multifactorial Inheritance | 1 | 2019 | 173 | 0.530 |
Why?
|
| ras Proteins | 3 | 2016 | 147 | 0.530 |
Why?
|
| Aquatic Organisms | 1 | 2017 | 9 | 0.520 |
Why?
|
| Health Status | 1 | 2019 | 367 | 0.510 |
Why?
|
| Mesoderm | 1 | 2017 | 105 | 0.510 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 2107 | 0.510 |
Why?
|
| Autophagy | 4 | 2022 | 421 | 0.510 |
Why?
|
| Ovarian Neoplasms | 2 | 2023 | 434 | 0.500 |
Why?
|
| Caenorhabditis elegans | 2 | 2017 | 252 | 0.500 |
Why?
|
| Culicidae | 2 | 2016 | 73 | 0.490 |
Why?
|
| Software | 2 | 2019 | 737 | 0.490 |
Why?
|
| Longevity | 1 | 2017 | 177 | 0.480 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2016 | 120 | 0.480 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 132 | 0.480 |
Why?
|
| Biomimetic Materials | 1 | 2015 | 9 | 0.470 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2017 | 199 | 0.470 |
Why?
|
| Immunoassay | 2 | 2026 | 125 | 0.470 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2015 | 44 | 0.460 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2017 | 602 | 0.460 |
Why?
|
| Biomarkers | 8 | 2022 | 3394 | 0.460 |
Why?
|
| Peptide Elongation Factor 1 | 1 | 2015 | 9 | 0.450 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2022 | 89 | 0.450 |
Why?
|
| Depsipeptides | 1 | 2015 | 16 | 0.450 |
Why?
|
| Bupivacaine | 1 | 2015 | 26 | 0.450 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2025 | 726 | 0.440 |
Why?
|
| Papua New Guinea | 7 | 2018 | 11 | 0.440 |
Why?
|
| Urologic Surgical Procedures | 1 | 2015 | 57 | 0.440 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 567 | 0.440 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2016 | 146 | 0.440 |
Why?
|
| Mutation | 10 | 2025 | 6131 | 0.440 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2014 | 18 | 0.430 |
Why?
|
| Bayes Theorem | 4 | 2026 | 308 | 0.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 1312 | 0.430 |
Why?
|
| RNA Splicing | 2 | 2026 | 237 | 0.420 |
Why?
|
| Liposomes | 1 | 2015 | 196 | 0.420 |
Why?
|
| Anesthetics, Local | 1 | 2015 | 86 | 0.420 |
Why?
|
| Antibody Formation | 5 | 2022 | 227 | 0.420 |
Why?
|
| Membrane Proteins | 5 | 2026 | 1602 | 0.420 |
Why?
|
| Protein Binding | 7 | 2021 | 1666 | 0.420 |
Why?
|
| Cell Survival | 8 | 2021 | 837 | 0.420 |
Why?
|
| Metabolic Syndrome | 1 | 2017 | 366 | 0.410 |
Why?
|
| Gene Expression Regulation | 4 | 2024 | 2355 | 0.410 |
Why?
|
| Cell Nucleus | 1 | 2016 | 569 | 0.410 |
Why?
|
| Pharmacogenetics | 1 | 2015 | 203 | 0.410 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 2026 | 261 | 0.410 |
Why?
|
| Apoptosis | 4 | 2020 | 1842 | 0.400 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 1395 | 0.400 |
Why?
|
| Antimalarials | 3 | 2021 | 47 | 0.400 |
Why?
|
| Follow-Up Studies | 9 | 2025 | 5186 | 0.400 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2024 | 2024 | 0.390 |
Why?
|
| Neoadjuvant Therapy | 3 | 2025 | 394 | 0.390 |
Why?
|
| Merozoites | 3 | 2019 | 6 | 0.390 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2022 | 170 | 0.390 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2014 | 163 | 0.390 |
Why?
|
| Carcinogenesis | 3 | 2022 | 342 | 0.390 |
Why?
|
| Vaccination | 3 | 2022 | 1041 | 0.370 |
Why?
|
| Longitudinal Studies | 6 | 2021 | 1485 | 0.370 |
Why?
|
| RNA, Small Interfering | 7 | 2020 | 667 | 0.370 |
Why?
|
| Young Adult | 14 | 2025 | 9995 | 0.370 |
Why?
|
| Robotic Surgical Procedures | 3 | 2025 | 222 | 0.370 |
Why?
|
| Aged, 80 and over | 11 | 2025 | 6781 | 0.350 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2022 | 613 | 0.350 |
Why?
|
| Recurrence | 5 | 2019 | 1482 | 0.340 |
Why?
|
| Sequence Analysis, DNA | 3 | 2015 | 1723 | 0.340 |
Why?
|
| Gene Library | 4 | 2023 | 211 | 0.330 |
Why?
|
| Infant | 15 | 2022 | 13269 | 0.330 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2020 | 998 | 0.330 |
Why?
|
| HCT116 Cells | 5 | 2020 | 62 | 0.330 |
Why?
|
| Base Sequence | 6 | 2025 | 2767 | 0.330 |
Why?
|
| Thailand | 6 | 2021 | 46 | 0.330 |
Why?
|
| Pancreatectomy | 1 | 2011 | 147 | 0.320 |
Why?
|
| Child, Preschool | 18 | 2022 | 14985 | 0.320 |
Why?
|
| Models, Genetic | 1 | 2013 | 748 | 0.320 |
Why?
|
| MAP Kinase Signaling System | 3 | 2017 | 305 | 0.320 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 480 | 0.310 |
Why?
|
| HeLa Cells | 3 | 2019 | 698 | 0.310 |
Why?
|
| Cohort Studies | 12 | 2024 | 5069 | 0.310 |
Why?
|
| DNA | 2 | 2021 | 1419 | 0.300 |
Why?
|
| Child | 24 | 2024 | 26165 | 0.290 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 985 | 0.290 |
Why?
|
| High-Throughput Screening Assays | 4 | 2017 | 116 | 0.280 |
Why?
|
| Oncogenes | 2 | 2020 | 163 | 0.280 |
Why?
|
| Lymph Node Excision | 2 | 2024 | 160 | 0.270 |
Why?
|
| Adolescent | 17 | 2022 | 20754 | 0.270 |
Why?
|
| Biological Ontologies | 2 | 2018 | 7 | 0.270 |
Why?
|
| Kenya | 5 | 2022 | 55 | 0.270 |
Why?
|
| Ubiquitin-Protein Ligases | 4 | 2025 | 361 | 0.260 |
Why?
|
| Immunotherapy | 4 | 2022 | 753 | 0.260 |
Why?
|
| Lymphatic Metastasis | 3 | 2025 | 427 | 0.260 |
Why?
|
| Public Health | 2 | 2022 | 272 | 0.250 |
Why?
|
| Blood Glucose | 1 | 2011 | 1106 | 0.250 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 1391 | 0.250 |
Why?
|
| Age of Onset | 2 | 2025 | 598 | 0.250 |
Why?
|
| Prevalence | 8 | 2022 | 2685 | 0.250 |
Why?
|
| ROC Curve | 2 | 2026 | 606 | 0.250 |
Why?
|
| Saccharomyces cerevisiae | 2 | 2026 | 399 | 0.250 |
Why?
|
| Incidence | 7 | 2024 | 3330 | 0.250 |
Why?
|
| Cell Proliferation | 4 | 2020 | 2476 | 0.240 |
Why?
|
| Down-Regulation | 2 | 2020 | 655 | 0.240 |
Why?
|
| Encephalitis Virus, Japanese | 1 | 2026 | 23 | 0.240 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2024 | 109 | 0.240 |
Why?
|
| Microsatellite Instability | 2 | 2025 | 38 | 0.240 |
Why?
|
| Drosophila melanogaster | 1 | 2012 | 850 | 0.240 |
Why?
|
| Chikungunya virus | 1 | 2026 | 30 | 0.240 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 1263 | 0.230 |
Why?
|
| Transistors, Electronic | 1 | 2025 | 2 | 0.230 |
Why?
|
| Indium | 1 | 2025 | 3 | 0.230 |
Why?
|
| Peptide Nucleic Acids | 1 | 2025 | 2 | 0.230 |
Why?
|
| Circulating MicroRNA | 1 | 2025 | 12 | 0.230 |
Why?
|
| HEK293 Cells | 4 | 2023 | 809 | 0.230 |
Why?
|
| Nanotubes, Carbon | 1 | 2025 | 15 | 0.230 |
Why?
|
| Brazil | 6 | 2024 | 116 | 0.230 |
Why?
|
| Cross Reactions | 1 | 2026 | 158 | 0.230 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2023 | 39 | 0.230 |
Why?
|
| Prostatic Neoplasms | 3 | 2023 | 1414 | 0.230 |
Why?
|
| Liquid Biopsy | 1 | 2025 | 14 | 0.220 |
Why?
|
| Promoter Regions, Genetic | 3 | 2023 | 1227 | 0.220 |
Why?
|
| Ghana | 2 | 2015 | 22 | 0.220 |
Why?
|
| Feathers | 1 | 2024 | 1 | 0.220 |
Why?
|
| Parrots | 1 | 2024 | 2 | 0.220 |
Why?
|
| Seasons | 2 | 2017 | 333 | 0.220 |
Why?
|
| Synthetic Lethal Mutations | 1 | 2024 | 11 | 0.220 |
Why?
|
| Pigments, Biological | 1 | 2024 | 8 | 0.220 |
Why?
|
| Pigmentation | 1 | 2024 | 35 | 0.220 |
Why?
|
| Exosomes | 1 | 2025 | 62 | 0.220 |
Why?
|
| Genes, Reporter | 2 | 2023 | 342 | 0.220 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2024 | 41 | 0.220 |
Why?
|
| West Nile virus | 1 | 2026 | 120 | 0.220 |
Why?
|
| Biosensing Techniques | 1 | 2025 | 79 | 0.220 |
Why?
|
| Zika Virus | 1 | 2026 | 149 | 0.210 |
Why?
|
| Antigens, Viral | 1 | 2026 | 392 | 0.210 |
Why?
|
| Homeostasis | 2 | 2026 | 715 | 0.210 |
Why?
|
| Arachnoid | 1 | 2024 | 8 | 0.210 |
Why?
|
| Primaquine | 1 | 2024 | 1 | 0.210 |
Why?
|
| West Nile Fever | 1 | 2026 | 143 | 0.210 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2025 | 194 | 0.210 |
Why?
|
| Dura Mater | 1 | 2024 | 29 | 0.210 |
Why?
|
| Xenopus Proteins | 1 | 2004 | 58 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 3 | 2022 | 379 | 0.200 |
Why?
|
| Immunoglobulin M | 2 | 2022 | 210 | 0.200 |
Why?
|
| Nuclear Proteins | 4 | 2017 | 1229 | 0.200 |
Why?
|
| Retinal Cone Photoreceptor Cells | 1 | 2024 | 74 | 0.200 |
Why?
|
| Phosphorylation | 3 | 2021 | 1577 | 0.200 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 890 | 0.200 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2020 | 914 | 0.190 |
Why?
|
| Operating Rooms | 1 | 2023 | 74 | 0.190 |
Why?
|
| Dysbiosis | 1 | 2024 | 145 | 0.190 |
Why?
|
| Plasmodium knowlesi | 1 | 2022 | 3 | 0.190 |
Why?
|
| Antibody Affinity | 1 | 2022 | 37 | 0.190 |
Why?
|
| Receptors, Androgen | 2 | 2023 | 415 | 0.190 |
Why?
|
| Snail Family Transcription Factors | 1 | 2022 | 27 | 0.190 |
Why?
|
| Genotype | 2 | 2019 | 2605 | 0.190 |
Why?
|
| Surgical Stapling | 1 | 2022 | 18 | 0.190 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 140 | 0.180 |
Why?
|
| Reoperation | 1 | 2025 | 832 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2025 | 2847 | 0.180 |
Why?
|
| Erythrocytes | 3 | 2020 | 187 | 0.180 |
Why?
|
| Cleft Lip | 1 | 2025 | 192 | 0.180 |
Why?
|
| Lymph Nodes | 1 | 2024 | 360 | 0.180 |
Why?
|
| Cleft Palate | 1 | 2025 | 219 | 0.180 |
Why?
|
| Peritoneum | 1 | 2022 | 36 | 0.180 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 227 | 0.180 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 102 | 0.180 |
Why?
|
| Immune System | 1 | 2022 | 99 | 0.180 |
Why?
|
| Prospective Studies | 4 | 2023 | 6423 | 0.180 |
Why?
|
| Spermatids | 1 | 2021 | 25 | 0.180 |
Why?
|
| Anastomosis, Surgical | 1 | 2022 | 175 | 0.180 |
Why?
|
| Disease Transmission, Infectious | 2 | 2019 | 74 | 0.180 |
Why?
|
| Dietary Fiber | 1 | 2021 | 77 | 0.170 |
Why?
|
| Molecular Sequence Data | 3 | 2013 | 3507 | 0.170 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2021 | 50 | 0.170 |
Why?
|
| Treatment Outcome | 7 | 2025 | 12860 | 0.170 |
Why?
|
| CTLA-4 Antigen | 1 | 2021 | 64 | 0.170 |
Why?
|
| Platinum Compounds | 1 | 2020 | 5 | 0.170 |
Why?
|
| Pemetrexed | 1 | 2020 | 9 | 0.170 |
Why?
|
| Suture Techniques | 1 | 2022 | 175 | 0.170 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2021 | 39 | 0.170 |
Why?
|
| Feedback, Physiological | 1 | 2020 | 66 | 0.160 |
Why?
|
| Sex Determination Processes | 1 | 2020 | 11 | 0.160 |
Why?
|
| Gene Expression Profiling | 4 | 2024 | 1827 | 0.160 |
Why?
|
| Perfusion | 1 | 2022 | 211 | 0.160 |
Why?
|
| Portal Vein | 1 | 2021 | 89 | 0.160 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 143 | 0.160 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2020 | 89 | 0.160 |
Why?
|
| Viruses | 1 | 2021 | 117 | 0.160 |
Why?
|
| Emergencies | 1 | 2021 | 176 | 0.160 |
Why?
|
| Thrombospondin 1 | 1 | 2020 | 23 | 0.160 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2020 | 42 | 0.160 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2020 | 44 | 0.160 |
Why?
|
| Fungal Proteins | 1 | 2020 | 135 | 0.160 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 3803 | 0.150 |
Why?
|
| Biopsy | 1 | 2023 | 1239 | 0.150 |
Why?
|
| Age Factors | 4 | 2019 | 2835 | 0.150 |
Why?
|
| Genes, Neoplasm | 1 | 2020 | 80 | 0.150 |
Why?
|
| DNA Transposable Elements | 1 | 2020 | 181 | 0.150 |
Why?
|
| Recombinant Proteins | 3 | 2017 | 1323 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 312 | 0.150 |
Why?
|
| Phenotype | 2 | 2019 | 4474 | 0.150 |
Why?
|
| Pacific Islands | 1 | 2018 | 5 | 0.150 |
Why?
|
| Computer Simulation | 2 | 2021 | 676 | 0.150 |
Why?
|
| Probiotics | 1 | 2021 | 224 | 0.150 |
Why?
|
| Cell Line | 6 | 2025 | 2579 | 0.150 |
Why?
|
| Nepal | 1 | 2018 | 25 | 0.150 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 43 | 0.140 |
Why?
|
| Tanzania | 2 | 2016 | 67 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 2106 | 0.140 |
Why?
|
| Multiprotein Complexes | 2 | 2021 | 197 | 0.140 |
Why?
|
| Africa South of the Sahara | 1 | 2018 | 121 | 0.140 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 20 | 0.140 |
Why?
|
| Immunity, Innate | 4 | 2016 | 405 | 0.140 |
Why?
|
| Calibration | 1 | 2018 | 92 | 0.140 |
Why?
|
| Acrylamides | 1 | 2018 | 27 | 0.140 |
Why?
|
| Geography | 1 | 2018 | 116 | 0.140 |
Why?
|
| Surgeons | 1 | 2023 | 289 | 0.140 |
Why?
|
| Interferon Regulatory Factor-3 | 2 | 2015 | 18 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 5 | 2021 | 4695 | 0.140 |
Why?
|
| Up-Regulation | 1 | 2020 | 833 | 0.140 |
Why?
|
| Starvation | 1 | 2017 | 17 | 0.140 |
Why?
|
| Autophagosomes | 1 | 2017 | 28 | 0.140 |
Why?
|
| Birds | 1 | 2017 | 49 | 0.130 |
Why?
|
| Insect Vectors | 2 | 2016 | 113 | 0.130 |
Why?
|
| Influenza in Birds | 1 | 2017 | 27 | 0.130 |
Why?
|
| Interferons | 2 | 2015 | 136 | 0.130 |
Why?
|
| Vesiculovirus | 2 | 2014 | 15 | 0.130 |
Why?
|
| Ethiopia | 1 | 2017 | 22 | 0.130 |
Why?
|
| Abdominal Injuries | 2 | 2010 | 119 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 810 | 0.130 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2017 | 29 | 0.130 |
Why?
|
| I-kappa B Kinase | 1 | 2017 | 56 | 0.130 |
Why?
|
| Phosphoproteins | 2 | 2016 | 454 | 0.130 |
Why?
|
| Disease Resistance | 1 | 2017 | 22 | 0.130 |
Why?
|
| Genome, Protozoan | 1 | 2017 | 26 | 0.130 |
Why?
|
| Caloric Restriction | 1 | 2017 | 106 | 0.130 |
Why?
|
| Follistatin-Related Proteins | 1 | 2016 | 1 | 0.130 |
Why?
|
| Porphyrins | 1 | 2016 | 8 | 0.130 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2016 | 32 | 0.130 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 252 | 0.130 |
Why?
|
| Influenza A virus | 1 | 2017 | 142 | 0.130 |
Why?
|
| Machine Learning | 1 | 2020 | 385 | 0.130 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2016 | 30 | 0.130 |
Why?
|
| Metabolome | 1 | 2019 | 325 | 0.120 |
Why?
|
| Transfection | 2 | 2011 | 961 | 0.120 |
Why?
|
| Aurora Kinase A | 1 | 2017 | 36 | 0.120 |
Why?
|
| Spatial Analysis | 1 | 2016 | 27 | 0.120 |
Why?
|
| Genes, Lethal | 1 | 2016 | 72 | 0.120 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 137 | 0.120 |
Why?
|
| Infant, Newborn | 4 | 2019 | 8493 | 0.120 |
Why?
|
| Toll-Like Receptor 3 | 2 | 2015 | 20 | 0.120 |
Why?
|
| Piperidines | 1 | 2018 | 230 | 0.120 |
Why?
|
| Basic Reproduction Number | 1 | 2016 | 2 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2021 | 1452 | 0.120 |
Why?
|
| Peptide Library | 1 | 2016 | 56 | 0.120 |
Why?
|
| Sporozoites | 1 | 2015 | 3 | 0.120 |
Why?
|
| Plasmodium ovale | 1 | 2015 | 2 | 0.120 |
Why?
|
| Tropical Climate | 1 | 2016 | 51 | 0.120 |
Why?
|
| Diet, High-Fat | 1 | 2017 | 264 | 0.120 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 109 | 0.120 |
Why?
|
| Lysosomes | 1 | 2017 | 269 | 0.120 |
Why?
|
| Mental Health | 1 | 2019 | 369 | 0.120 |
Why?
|
| Acetyltransferases | 1 | 2015 | 75 | 0.120 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2015 | 37 | 0.120 |
Why?
|
| Fatty Liver | 1 | 2017 | 221 | 0.120 |
Why?
|
| Asymptomatic Infections | 3 | 2022 | 39 | 0.120 |
Why?
|
| Thiolester Hydrolases | 1 | 2015 | 6 | 0.110 |
Why?
|
| Simuliidae | 1 | 2015 | 4 | 0.110 |
Why?
|
| RNA Polymerase II | 1 | 2015 | 88 | 0.110 |
Why?
|
| DNA Helicases | 1 | 2017 | 234 | 0.110 |
Why?
|
| Aspartic Acid | 1 | 2015 | 78 | 0.110 |
Why?
|
| CA-19-9 Antigen | 2 | 2026 | 11 | 0.110 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2015 | 5 | 0.110 |
Why?
|
| Onchocerca volvulus | 1 | 2015 | 16 | 0.110 |
Why?
|
| CA-125 Antigen | 2 | 2026 | 14 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2016 | 622 | 0.110 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2026 | 26 | 0.110 |
Why?
|
| Onchocerciasis | 1 | 2015 | 22 | 0.110 |
Why?
|
| Vaccines, Subunit | 1 | 2015 | 74 | 0.110 |
Why?
|
| DNA Repair | 2 | 2015 | 575 | 0.110 |
Why?
|
| Eye Proteins | 1 | 2016 | 238 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 265 | 0.110 |
Why?
|
| Piperazines | 1 | 2017 | 270 | 0.110 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 286 | 0.110 |
Why?
|
| Introns | 2 | 2026 | 281 | 0.110 |
Why?
|
| Melanesia | 3 | 2020 | 6 | 0.110 |
Why?
|
| Immunization, Secondary | 1 | 2015 | 118 | 0.110 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 373 | 0.110 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2014 | 37 | 0.110 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2015 | 69 | 0.110 |
Why?
|
| Vesicular Transport Proteins | 1 | 2015 | 140 | 0.110 |
Why?
|
| Receptors, Calcitriol | 1 | 2014 | 60 | 0.110 |
Why?
|
| Gambia | 1 | 2014 | 26 | 0.110 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2015 | 178 | 0.110 |
Why?
|
| NF-kappa B | 1 | 2016 | 442 | 0.110 |
Why?
|
| Genome | 1 | 2016 | 465 | 0.100 |
Why?
|
| Glycolysis | 1 | 2014 | 175 | 0.100 |
Why?
|
| Genetic Variation | 2 | 2024 | 1556 | 0.100 |
Why?
|
| Genomic Instability | 1 | 2015 | 244 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2014 | 362 | 0.100 |
Why?
|
| Pain Measurement | 1 | 2015 | 351 | 0.100 |
Why?
|
| Base Composition | 1 | 2013 | 70 | 0.100 |
Why?
|
| Length of Stay | 3 | 2015 | 1395 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 264 | 0.100 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 228 | 0.100 |
Why?
|
| Calcium | 1 | 2017 | 1027 | 0.100 |
Why?
|
| Pain Management | 1 | 2015 | 204 | 0.100 |
Why?
|
| Vitamin D | 1 | 2014 | 198 | 0.090 |
Why?
|
| CRISPR-Cas Systems | 1 | 2016 | 318 | 0.090 |
Why?
|
| Transplantation, Homologous | 1 | 2014 | 669 | 0.090 |
Why?
|
| RNA | 1 | 2016 | 520 | 0.090 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2012 | 20 | 0.090 |
Why?
|
| DNA Primers | 1 | 2013 | 606 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 426 | 0.090 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 253 | 0.090 |
Why?
|
| Cytokines | 1 | 2018 | 1335 | 0.090 |
Why?
|
| Transcriptome | 1 | 2019 | 1129 | 0.090 |
Why?
|
| Antigens, Neoplasm | 1 | 2015 | 398 | 0.090 |
Why?
|
| Mitochondria | 1 | 2017 | 763 | 0.090 |
Why?
|
| Protein Biosynthesis | 1 | 2015 | 575 | 0.090 |
Why?
|
| Muscle Proteins | 1 | 2014 | 403 | 0.090 |
Why?
|
| Peru | 2 | 2022 | 54 | 0.090 |
Why?
|
| Brain | 1 | 2024 | 3186 | 0.090 |
Why?
|
| Laparotomy | 2 | 2010 | 138 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2919 | 0.090 |
Why?
|
| Fluorescence | 2 | 2022 | 94 | 0.090 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2011 | 20 | 0.090 |
Why?
|
| Hospitals, University | 1 | 2011 | 100 | 0.090 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 1972 | 0.090 |
Why?
|
| Embryo, Nonmammalian | 1 | 2012 | 139 | 0.090 |
Why?
|
| Cryosurgery | 1 | 2011 | 51 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2011 | 269 | 0.080 |
Why?
|
| Medical Futility | 1 | 2010 | 40 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2011 | 330 | 0.080 |
Why?
|
| Exome | 1 | 2015 | 1075 | 0.080 |
Why?
|
| Kinetics | 2 | 2022 | 1087 | 0.080 |
Why?
|
| Liver | 1 | 2017 | 1797 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2011 | 175 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2011 | 937 | 0.080 |
Why?
|
| Cystectomy | 1 | 2010 | 141 | 0.080 |
Why?
|
| Graft vs Host Disease | 1 | 2014 | 682 | 0.070 |
Why?
|
| Trauma Centers | 1 | 2010 | 205 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1889 | 0.070 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2010 | 160 | 0.070 |
Why?
|
| Cells, Cultured | 2 | 2012 | 2905 | 0.070 |
Why?
|
| Africa | 2 | 2021 | 140 | 0.070 |
Why?
|
| Endoscopy | 1 | 2010 | 270 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2011 | 1215 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2015 | 1925 | 0.070 |
Why?
|
| Disease Eradication | 2 | 2020 | 40 | 0.070 |
Why?
|
| Catheter Ablation | 1 | 2011 | 320 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2025 | 628 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2020 | 589 | 0.070 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2012 | 975 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 479 | 0.060 |
Why?
|
| Metabolomics | 2 | 2022 | 504 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2011 | 420 | 0.060 |
Why?
|
| Alleles | 2 | 2025 | 1685 | 0.060 |
Why?
|
| Logistic Models | 1 | 2011 | 1799 | 0.060 |
Why?
|
| Glutamine | 2 | 2019 | 204 | 0.060 |
Why?
|
| Trypsin | 1 | 2006 | 68 | 0.060 |
Why?
|
| Genes, myc | 2 | 2017 | 95 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2018 | 701 | 0.060 |
Why?
|
| Drosophila Proteins | 1 | 2012 | 786 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2004 | 582 | 0.060 |
Why?
|
| Transcription Factor AP-2 | 1 | 2025 | 22 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2010 | 488 | 0.060 |
Why?
|
| Limit of Detection | 1 | 2025 | 73 | 0.060 |
Why?
|
| Interferon Regulatory Factors | 1 | 2025 | 45 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2019 | 528 | 0.060 |
Why?
|
| RNA Splice Sites | 1 | 2025 | 92 | 0.060 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2025 | 20 | 0.060 |
Why?
|
| Protein Kinases | 2 | 2004 | 319 | 0.060 |
Why?
|
| Appendectomy | 1 | 2025 | 88 | 0.060 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2024 | 19 | 0.060 |
Why?
|
| Disease Progression | 1 | 2011 | 2205 | 0.060 |
Why?
|
| Nucleic Acid Conformation | 1 | 2025 | 180 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2025 | 277 | 0.050 |
Why?
|
| Color | 1 | 2024 | 30 | 0.050 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2007 | 214 | 0.050 |
Why?
|
| Smad4 Protein | 1 | 2025 | 58 | 0.050 |
Why?
|
| Algorithms | 3 | 2017 | 1680 | 0.050 |
Why?
|
| Stomach | 1 | 2007 | 271 | 0.050 |
Why?
|
| Keratinocytes | 1 | 2024 | 73 | 0.050 |
Why?
|
| Receptor, Notch1 | 1 | 2025 | 77 | 0.050 |
Why?
|
| Poly I-C | 2 | 2015 | 20 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 974 | 0.050 |
Why?
|
| Cambodia | 1 | 2024 | 15 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 3815 | 0.050 |
Why?
|
| Colectomy | 1 | 2025 | 90 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2022 | 1498 | 0.050 |
Why?
|
| Forests | 1 | 2024 | 14 | 0.050 |
Why?
|
| Colorectal Surgery | 1 | 2004 | 12 | 0.050 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2024 | 18 | 0.050 |
Why?
|
| Subarachnoid Space | 1 | 2024 | 23 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2004 | 17 | 0.050 |
Why?
|
| Aminoquinolines | 1 | 2024 | 34 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2011 | 3682 | 0.050 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2024 | 45 | 0.050 |
Why?
|
| Xenopus laevis | 1 | 2004 | 119 | 0.050 |
Why?
|
| Cerebrospinal Fluid | 1 | 2024 | 100 | 0.050 |
Why?
|
| Protein Domains | 1 | 2024 | 253 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2024 | 434 | 0.050 |
Why?
|
| Veins | 1 | 2024 | 96 | 0.050 |
Why?
|
| Registries | 1 | 2010 | 1605 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2017 | 202 | 0.050 |
Why?
|
| beta Catenin | 1 | 2025 | 199 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2024 | 406 | 0.050 |
Why?
|
| Biological Transport | 1 | 2024 | 332 | 0.050 |
Why?
|
| Ubiquitin | 1 | 2004 | 132 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2023 | 130 | 0.050 |
Why?
|
| Cell Death | 2 | 2014 | 233 | 0.050 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2025 | 246 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2025 | 372 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2004 | 175 | 0.050 |
Why?
|
| Neoplastic Processes | 1 | 2022 | 6 | 0.050 |
Why?
|
| Image-Guided Biopsy | 1 | 2022 | 42 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2024 | 788 | 0.050 |
Why?
|
| Acetyl Coenzyme A | 1 | 2022 | 16 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2022 | 58 | 0.050 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 84 | 0.050 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 44 | 0.050 |
Why?
|
| Telomerase | 2 | 2014 | 153 | 0.050 |
Why?
|
| Plant Proteins | 1 | 2002 | 86 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 122 | 0.040 |
Why?
|
| Acetylation | 1 | 2022 | 188 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 38 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 185 | 0.040 |
Why?
|
| ral GTP-Binding Proteins | 1 | 2021 | 4 | 0.040 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 43 | 0.040 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2021 | 35 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2022 | 204 | 0.040 |
Why?
|
| Fertilization | 1 | 2021 | 43 | 0.040 |
Why?
|
| Blastocyst | 1 | 2021 | 72 | 0.040 |
Why?
|
| Asia, Southeastern | 1 | 2021 | 22 | 0.040 |
Why?
|
| eIF-2 Kinase | 1 | 2021 | 35 | 0.040 |
Why?
|
| Cholangiography | 1 | 2021 | 13 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 889 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2024 | 275 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 1300 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 1076 | 0.040 |
Why?
|
| Cytosol | 1 | 2021 | 139 | 0.040 |
Why?
|
| Mammals | 1 | 2022 | 255 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2021 | 70 | 0.040 |
Why?
|
| Gene Order | 1 | 2020 | 82 | 0.040 |
Why?
|
| Cholecystectomy | 1 | 2021 | 57 | 0.040 |
Why?
|
| Indocyanine Green | 1 | 2021 | 51 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 157 | 0.040 |
Why?
|
| Embryonic Stem Cells | 1 | 2021 | 157 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 216 | 0.040 |
Why?
|
| Epitopes | 1 | 2022 | 322 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2026 | 2565 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2021 | 495 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 319 | 0.040 |
Why?
|
| Risk Factors | 3 | 2025 | 10942 | 0.040 |
Why?
|
| Embryonic Development | 1 | 2021 | 199 | 0.040 |
Why?
|
| Plasmids | 1 | 2020 | 451 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2019 | 64 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 301 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2020 | 189 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 499 | 0.040 |
Why?
|
| Complement Fixation Tests | 1 | 2019 | 29 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2023 | 435 | 0.040 |
Why?
|
| Complement C1q | 1 | 2019 | 18 | 0.040 |
Why?
|
| Time Factors | 3 | 2020 | 6190 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2019 | 110 | 0.040 |
Why?
|
| Trauma Severity Indices | 2 | 2010 | 87 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 783 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 161 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 145 | 0.040 |
Why?
|
| Virus Diseases | 1 | 2021 | 284 | 0.040 |
Why?
|
| Communication | 1 | 2023 | 531 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 194 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2024 | 2342 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 722 | 0.030 |
Why?
|
| Merozoite Surface Protein 1 | 1 | 2017 | 11 | 0.030 |
Why?
|
| Parasitemia | 1 | 2017 | 26 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 113 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 599 | 0.030 |
Why?
|
| Rats | 1 | 2004 | 3397 | 0.030 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2011 | 34 | 0.030 |
Why?
|
| Half-Life | 1 | 2017 | 150 | 0.030 |
Why?
|
| Commerce | 1 | 2017 | 57 | 0.030 |
Why?
|
| Cell-Free System | 1 | 2017 | 62 | 0.030 |
Why?
|
| Immune Sera | 1 | 2017 | 55 | 0.030 |
Why?
|
| China | 1 | 2017 | 281 | 0.030 |
Why?
|
| Triticum | 1 | 2017 | 27 | 0.030 |
Why?
|
| Databases, Protein | 1 | 2017 | 63 | 0.030 |
Why?
|
| Uganda | 1 | 2017 | 84 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2017 | 89 | 0.030 |
Why?
|
| Anoikis | 1 | 2016 | 8 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2017 | 65 | 0.030 |
Why?
|
| Protein Stability | 1 | 2017 | 165 | 0.030 |
Why?
|
| Cyclopropanes | 1 | 2017 | 67 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2017 | 201 | 0.030 |
Why?
|
| Equatorial Guinea | 1 | 2015 | 1 | 0.030 |
Why?
|
| RNA Editing | 1 | 2016 | 32 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2017 | 165 | 0.030 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2015 | 16 | 0.030 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2015 | 16 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2016 | 257 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2015 | 75 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2015 | 33 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 89 | 0.030 |
Why?
|
| K562 Cells | 1 | 2015 | 97 | 0.030 |
Why?
|
| Exodeoxyribonucleases | 1 | 2015 | 51 | 0.030 |
Why?
|
| Germ Cells | 1 | 2017 | 200 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2015 | 100 | 0.030 |
Why?
|
| Immunization Schedule | 1 | 2015 | 111 | 0.030 |
Why?
|
| Ovum | 1 | 2015 | 13 | 0.030 |
Why?
|
| Africa, Western | 1 | 2015 | 15 | 0.030 |
Why?
|
| Pupa | 1 | 2015 | 20 | 0.030 |
Why?
|
| Response Elements | 1 | 2015 | 104 | 0.030 |
Why?
|
| Exocytosis | 1 | 2015 | 66 | 0.030 |
Why?
|
| Placebos | 1 | 2015 | 225 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 100 | 0.030 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2014 | 11 | 0.030 |
Why?
|
| BRCA2 Protein | 1 | 2015 | 56 | 0.030 |
Why?
|
| Genome, Human | 2 | 2013 | 1322 | 0.030 |
Why?
|
| Glucose | 1 | 2019 | 854 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 2015 | 78 | 0.030 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Madin Darby Canine Kidney Cells | 1 | 2014 | 10 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2015 | 300 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2016 | 155 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1153 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 397 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2015 | 154 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 899 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 161 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 417 | 0.030 |
Why?
|
| Vero Cells | 1 | 2014 | 115 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2015 | 222 | 0.030 |
Why?
|
| Larva | 1 | 2015 | 249 | 0.030 |
Why?
|
| Temperature | 1 | 2015 | 289 | 0.030 |
Why?
|
| Climate Change | 1 | 2015 | 66 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2025 | 3425 | 0.030 |
Why?
|
| Bronchi | 1 | 2014 | 98 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2014 | 155 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 490 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2014 | 132 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2017 | 357 | 0.030 |
Why?
|
| Indoles | 1 | 2015 | 199 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 206 | 0.030 |
Why?
|
| United States | 2 | 2025 | 11827 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2015 | 585 | 0.030 |
Why?
|
| Dogs | 1 | 2014 | 615 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2017 | 451 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2016 | 396 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 543 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1710 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2015 | 295 | 0.020 |
Why?
|
| Testis | 1 | 2015 | 398 | 0.020 |
Why?
|
| Systems Biology | 1 | 2013 | 60 | 0.020 |
Why?
|
| Quality of Life | 1 | 2022 | 2071 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 419 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2015 | 225 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2015 | 600 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 583 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2015 | 769 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 714 | 0.020 |
Why?
|
| Interferon-beta | 1 | 2012 | 56 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 1 | 2012 | 41 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 512 | 0.020 |
Why?
|
| Histones | 1 | 2015 | 545 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2012 | 245 | 0.020 |
Why?
|
| Computational Biology | 1 | 2017 | 868 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2015 | 1627 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 392 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2004 | 3112 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 1004 | 0.020 |
Why?
|
| Ohio | 1 | 2011 | 87 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 63 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 541 | 0.020 |
Why?
|
| Genes, ras | 1 | 2011 | 98 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 2408 | 0.020 |
Why?
|
| Laparoscopes | 1 | 2010 | 5 | 0.020 |
Why?
|
| Urinary Diversion | 1 | 2010 | 16 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 307 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2014 | 895 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 60 | 0.020 |
Why?
|
| Pelvis | 1 | 2010 | 71 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 382 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2015 | 797 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 1031 | 0.020 |
Why?
|
| Pregnancy | 1 | 2021 | 7380 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 541 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3388 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1125 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2012 | 857 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 3815 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 813 | 0.020 |
Why?
|
| Shock, Traumatic | 1 | 2007 | 6 | 0.020 |
Why?
|
| Michigan | 1 | 2007 | 46 | 0.020 |
Why?
|
| Inflammation | 1 | 2014 | 1473 | 0.020 |
Why?
|
| Morbidity | 1 | 2007 | 259 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2010 | 1065 | 0.010 |
Why?
|
| Urban Population | 1 | 2007 | 273 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2004 | 75 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 306 | 0.010 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2002 | 12 | 0.010 |
Why?
|
| Sorbitol | 1 | 2002 | 8 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2002 | 111 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2002 | 87 | 0.010 |
Why?
|
| RNA, Double-Stranded | 1 | 2002 | 57 | 0.010 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2002 | 56 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 105 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2002 | 293 | 0.010 |
Why?
|
| Ligands | 1 | 2002 | 486 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2002 | 300 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 1215 | 0.010 |
Why?
|
| Drosophila | 1 | 2002 | 794 | 0.010 |
Why?
|